CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Essajee, S. M.
Right arrow Articles by Borkowsky, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Essajee, S. M.
Right arrow Articles by Borkowsky, W.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, January 2002, p. 79-82, Vol. 9, No. 1
1071-412X/01/$04.00+0     DOI: 10.1128/CDLI.9.1.79-82.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Recombinant Glycoprotein Vaccines for Human Immunodeficiency Virus-Infected Children and Their Effects on Viral Quasispecies

Shaffiq M. Essajee,1* Ram Yogev,2 Henry Pollack,1 Bryan Greenhouse,1 Keith Krasinski,1 and William Borkowsky1

New York University School of Medicine, New York, New York,1 Northwestern University Medical School, Chicago, Illinois2

Received 16 May 2001/ Returned for modification 8 August 2001/ Accepted 5 October 2001

In individuals infected with human immunodeficiency virus type 1 (HIV-1), specific immunity is associated with a more diverse viral repertoire and slower disease progression. Attempts to enhance antiviral immunity with therapeutic vaccination have shown that recombinant glycoprotein (RGP) vaccines are safe, well tolerated, and immunogenic, but the effect of RGP vaccines on the viral repertoire is unknown. We evaluated diversification of the viral envelope in 12 HIV-infected children who received placebo or RGP vaccines. At baseline, 11 of 12 patients had multiple viral variants. On follow-up 6 months later, children who had a strong vaccine-associated lymphoproliferative immune response showed less viral diversification than those in whom the immune response was weak or absent. These results suggest that the immune response elicited by RGP vaccines does not exert a significant selection pressure on the viral quasispecies and therefore may not be helpful in changing the course of the disease.

* Corresponding author. Mailing address: Department of Pediatrics, Division of Infectious Diseases, New York University School of Medicine, 550 First Avenue, New York, NY 10016. Phone: (212) 263-1534. Fax: (212) 263-7806. E-mail: shaffiq.essajee{at}med.nyu.edu.

Clinical and Diagnostic Laboratory Immunology, January 2002, p. 79-82, Vol. 9, No. 1
1071-412X/01/$04.00+0     DOI: 10.1128/CDLI.9.1.79-82.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2002 by the American Society for Microbiology. All rights reserved.